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Abstract
Human leukocyte antigens (HLA) are an important family of genes involved in the immune
system. Their primary function is to allow the host immune system to be able to distinguish
between self and non-self peptides—e.g. derived from invading pathogens. However, these
genes have also been implicated in immune-mediated adverse drug reactions (ADRs), pre-
senting a problem to patients, clinicians and pharmaceutical companies. We have previ-
ously developed the Allele Frequency Net Database (AFND) that captures the allelic and
haplotype frequencies for these HLA genes across many healthy populations from around
the world. Here, we report the development and release of the HLA-ADR database that cap-
tures data from publications where HLA alleles and haplotypes have been associated with
ADRs (e.g. Stevens–Johnson Syndrome/toxic epidermal necrolysis and drug-induced liver
injury). HLA-ADR was created by using data obtained through systematic review of the lit-
erature and semi-automated literature mining. The database also draws on data already
present in AFND allowing users to compare and analyze allele frequencies in both ADR pa-
tients and healthy populations. The HLA-ADR database provides clinicians and researchers
with a centralized resource from which to investigate immune-mediated ADRs.
Database URL: http://www.allelefrequencies.net/hla-adr/.
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Adverse drug reactions (ADRs) are a major problem faced
by clinicians and pharmaceutical companies, demonstrated
by the fact that approximately 6–7% of hospital admissions
in the UK have been attributed to ADRs (1, 2). In addition,
3–5% of newly approved drugs in Europe and North
America (approved between 2002–11 and 1990–09, re-
spectively) were withdrawn for safety reasons, with hepato-
toxicity (an ADR) being the second most commonly cited
reason in both geographic regions after cardiovascular
events (3, 4).
Historically, there have been two categories of ADRs:
type A (‘on target’) and type B (‘off target’ or ‘idiosyn-
cratic’) (5). Type A reactions were described as observed
responses that augment the known pharmacological effects
of the drug, are dose dependent and predictable. Typical
causes for type A reactions include inter-individual vari-
ability in pharmacokinetics such as increased or impaired
absorption, distribution, metabolism or excretion of the
drug. Idiosyncratic or type B ADRs are described as rare,
not seen in most people being treated within the standard
therapeutic dose range, but can potentially cause severe
morbidity and possibly death. They are thought to be im-
mune mediated (6) and in many cases the human leukocyte
antigen (HLA) genes have been associated with these reac-
tions (7, 8). As a result of these associations, it has been
argued that referring to type B reactions as ‘unpredictable’
and ‘not dose dependant’ is largely incorrect and the defin-
ition of ‘off-target’ ADRs should be updated to reflect this
(9, 10). Because type B reactions only contribute to 20% of
all ADRs (11), the manifestations of the adverse reactions
may not be observed in patients until the late stages of
drug development or after general release, after many pa-
tients have been exposed to the drug. As well as the risks to
patients, the ADRs can lead to post-marketing product
withdrawal and significant financial loss due to the huge
investment in drug development and manufacturing
demands.
Immune-mediated ADRs can be observed in specific
ethnic groups and have been reported to be HLA allele
associated (12). The HLA genes are the most polymorphic
in the human genome, with 13 840 known alleles (in
October 2015; 10 297 class I and 3543 class II alleles) (13).
However, the HLA genetic component does not explain all
the contributing aspects to ADRs and there are likely other
components including environment (diet, smoking, alcohol
consumption etc.), host risk factors such as BMI, genetics,
co-morbidities and co-administered drugs, which may also
contribute to the onset of ADRs (8, 14).
Due to the extremely high number of alleles for some of
the HLA genes, a nomenclature of HLA alleles was de-
veloped (15). All HLA alleles are given an ‘HLA’ prefix
followed by a hyphen and the name of the gene (e.g.
‘HLA-A’) this is then followed by an asterisk (*) and a ser-
ies of grouped numbers or fields separated by colons (e.g.
HLA-B*57:01). The first field of numbers refers to the al-
lele group (antigen/serotype). Alleles belonging to the same
antigenic group will share the same number. The second
field of numbers defines the specific HLA protein (e.g.
HLA-B*57:01 is a part of the same antigenic group as
HLA-B*57:03, but the protein sequences for these alleles
differ by two amino acid residues). Additional fields (e.g.
HLA-A*01:01:01:01) refer to synonymous changes in the
protein-coding DNA sequence, i.e. causing no change in
the protein sequence (third group) or changes in intronic
regions (fourth group). In the rest of the article, we typic-
ally refer to specific proteins (second field) for discussing
HLA alleles.
In the field of pharmacogenomics, there are two main
study approaches that are implemented when trying to de-
termine the genetic components of HLA-induced ADRs.
These are genome-wide association studies (16, 17) and
case–control candidate gene studies (18, 19). Both
approaches have helped to identify HLA alleles associated
with increased risk of developing ADRs with some of the
highest odds ratios in medical literature. One of the ex-
amples is an association (P ¼ 3:13 1027; OR ¼
2504; 95% CI : 126–49 522) between HLA-A*15:02
and the most severe form of carbamazepine-induced hyper-
sensitivity termed Stevens–Johnson syndrome (SJS) (18).
Another example includes an association between HLA-
B*57:01 and abacavir-induced hypersensitivity where it
has been demonstrated that the drug is able to bind non-
covalently to the HLA-B*57:01 protein (12).
It has been reported that HLA-allele-associated ADRs
are more prevalent in certain populations, e.g. there is
greater frequency of reported cases of carbamazepine
induced SJS associated with HLA-B*15:02 in Han Chinese
populations as compared to Caucasians and ethnic
Japanese or Koreans (18, 20)—an allele found at relatively
high frequency in East and Southeast Asia. Conversely, the
presence of the HLA-A*31:01 allele is an important pre-
dictor for carbamazepine hypersensitivity in individuals of
European descent (21).
Given the rare occurrence of severe ADRs and huge ra-
cial variability in the frequency of HLA alleles, only a rela-
tively small number of individuals are reported in most
studies that investigate ADRs associated with HLAs, lead-
ing to statistical analysis with low power. Rarity of severe
ADRs also leaves researchers with great challenges for pre-
dicting, diagnosing and treating ADRs during drug devel-
opment and clinical trials. One of the methods of
addressing the potential risk to the patient for drugs
known to induce ADRs is to implement genetic screening
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before the administration of the drug to determine whether
a patient carries a known high-risk allele for this treatment,
and in such cases, provide the patient with an alternative
treatment therapy. This approach has already been effect-
ive in reducing ADRs in HIV patients who were prescribed
abacavir or epileptic patients treated with carbamazepine.
Patients were screened for the risk alleles (HLA-B*57:01
or B*15:02, respectively) and, if positive, provided with al-
ternative treatment, reducing the incidence of drug-hyper-
sensitivity reactions (22, 23).
With the research into ADRs becoming more wide-
spread, it has become ever more important for clinicians,
researchers and pharmaceutical companies to keep up to
date with the information that is available. To assist the
HLA and pharmacogenetic community, we have developed
a web-based database to synthesize the evidence and en-
able digital data access. To achieve this, we have per-
formed a systematic review and collated data sets from the
literature, designed and implemented a relational database
and created webpages to allow users to access these data,
called the HLA-ADR. The new database has been imple-
mented within the wider Allele Frequency Net Database
(AFND), which stores large collections of data on the allele
and haplotype frequencies for healthy, worldwide popula-
tions (24), as well as modules for exploring immunogenetic
disease associations (25). HLA-ADR provides a resource
that not only facilitates meta-analyses but also enables
users to further their investigations by using resources
available with the main AFND website, e.g. on the inci-




In order to populate the database, we conducted a sys-
tematic review to identify studies that contained the rele-
vant data. We developed a search protocol, using
internationally accepted standards, which was followed
during this systematic review. The details of the protocol
are laid out below and include the search strategy, the in-
clusion/exclusion criteria, method of screening and data
extraction.
Search strategy
Searches were performed using the Medline, HuGE
Navigator (26) and EMBASE literature databases. Search
strategies were developed for MEDLINE and EMBASE
(full details on the search strategy are available in the
Supplementary file). These searches aimed at capturing
studies in relation to adverse drug reactions that were asso-
ciated with HLA alleles. HuGE Navigator utilizes MeSH
terms (Medical Subject Headings: a controlled vocabulary
of keywords) within the searches and incorporates syn-
onymous terms within the results, therefore, using the term
‘Drug Toxicity and HLA’ for interrogating this database
was deemed sufficient to capture the appropriate studies
for inclusion in this review. A supplementary search was
also performed in Medline using specific drug names fol-
lowed by the phrase ‘(hypersensitivity OR pharmacogenet-
ics OR HLA)’. The drugs were selected based on those
reported in the HuGE Navigator search and also from re-
view articles (7, 8). The PubMed ID numbers (PMID) for
all search results were collected into a list, and duplicate
PMIDs were removed. Restrictions were applied to only
search for publications written in English.
Eligibility criteria
Details of how eligible studies were determined are pre-
sented in Table 1. In short, only case–control studies that
investigated ADRs in patients and provided statistical evi-
dence of the association were included. In relation to HLA
typing in these studies, only investigations where the HLA
genes of the patient–control cohort were genotyped to pro-
tein level (‘second field resolution’ or above) were
included. This was decided because it has been demon-
strated, at least for abacavir, that alleles within the same
antigenic group do not elicit the same ADR risk profile
(12). As such, we feel the small number of studies with
Table 1. Inclusion criteria for the literature review.
Population Patients with a hypersensitivity reaction to drugs administered as part of standard treatment
Study design Retrospective and prospective case-controlled studies, randomised controlled trials
Statistical evidence Provided statistical evidence e.g. P values, OR (95% CI) to determine the strength of the association.
HLA typing Investigations where patient and control HLA status was determined to the protein level (high resolution typing
sometimes referred to as ‘four-digit resolution’).
Studies where the HLA allele were genotype within the gene itself, i.e. not using proxy SNPs.
Study date A formal systematic review was performed covering studies with the publication year between 2000 and the time of
the search (April 2014) as described in the Materials and Methods section, followed by additional semi-auto-
mated searching covering April 2014 to Aug 2015 and also 1995 to 1999 (see additional studies).
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HLA typing to only the first field do not greatly contribute
to understanding. However, studies were included if a
mixture of high- and low-resolution typing had been
performed.
In addition, we only included studies in which the HLA
alleles were genotyped using any recognized method able
to determine high-resolution allele calls with high confi-
dence. We chose to exclude studies in which SNP-based
proxy (tagging) methods were used, i.e. with SNPs outside
the gene, elsewhere on the chromosome. (Proxy) SNP tag-
ging methods have been shown to be unreliable across dif-
ferent populations because they rely on the SNP tag to be
in perfect linkage disequilibrium with the allele of interest.
For example, in the case of SNP rs2395029 as a marker for
HLA-B*57:01 abacavir hypersensitivity, see (27) for NCBI
dbSNP for these SNP designations, the tag SNP was re-
ported to be in perfect linkage disequilibrium with the
HLA-B*57:01 allele in a Mexican population (28); how-
ever, this was not seen across all populations (29, 30). In
addition, HLA-DQA1*01:02, which has been associated
(as part of a haplotype) with lumiracoxib hepatotoxicity in
Caucasians, uses the SNPs rs9270986 and rs3129900 as
proxy markers (31). However, when investigated in other
populations, the use of these tags was shown to be limited
(32). In fact, an investigation by de Bakker et al. (33) dem-
onstrated that the same allele will require a different SNP
tags in different populations, e.g. HLA-A*31:01, for carba-
mazepine hypersensitivity would require the tag SNPs:
rs1061235 in Caucasians; rs3823318 and rs1061235 in
Chinese and rs1061235 and rs1150739 in Japanese popu-
lations. Therefore, the clinical relevance of using this tag
SNP is limited as multiple tags for each allele would be
required to cover all populations and patient backgrounds
will need to be taken into account in clinical settings. This
would also limit the ability to perform meta-analyses on
the data. As a result, a decision was taken to exclude stud-
ies where the patients HLA status was determined via tag
SNPs.
More recently, technologies have been developed
whereby HLA alleles can be imputed using multiple SNP
positions—e.g. HIBAG (34). Earlier algorithms using simi-
lar method were limited as they required extremely large
ethnic-based cohorts as training sets in order to make ac-
curate predictions. Such training set data are not always
available, as a result, alleles that are rare in these popula-
tions are difficult to call accurately (35). For this reason,
we chose not to include studies that used the early methods
of imputation in our systematic review. However, as newer
algorithms, such as the above-mentioned HIBAG, are
emerging, which are able to overcome these limitations, we
may change our inclusion/exclusion criteria in future up-
dates to the database to reflect these advances.
Literature screening
The studies passed through two stages of screening to de-
termine eligibility. The first stage involved reviewing the
titles and abstracts of the studies identified in the literature
search to determine relevance. The second stage involved
obtaining and examining the full paper to assess if they ful-
filled the eligibility criteria. In circumstances where the full
paper was unavailable (n¼ 22), the study was not
included. The selected studies were also assessed by a se-
cond reviewer with discrepancies being resolved through
discussion.
Data extraction
Data from the included studies were extracted to a spread-
sheet document by three reviewers and independently
checked by two reviewers. Examples of the types of data
that were extracted are provided in Supplementary file 1.
Additional notes that were considered relevant were also
recorded—e.g. in some cases in the literature, the associ-
ation is reported as less than the significance threshold (e.
g. as ‘<0.05’), we report this as ‘0.05’ with a note stating
this fact.
Additional studies
Because the systematic review was conducted, 11 new
studies have been published that meet the inclusion criteria
of the systematic review and were identified using a fol-
low-up semi-automated search. The data from these stud-
ies have been extracted and included in the HLA-ADR
database. The semi-automated search involved re-conduct-
ing the supplementary Medline search as described in
Materials and Methods section and applying date filters
coving publications released between April 2014 and
August 2015. The first-stage screening process was con-
ducted using a computer script that analyzes the titles and
abstracts of the studies for keywords (drug names, refer-
ences to HLA alleles and references to ADRs) and high-
lighting these articles for the second-stage review process,
which remained a manual process as described above. This
search was also repeated for studies published between
1995 and 1999 where an additional five studies were iden-
tified, meaning a total of 16 studies were identified via this
method. We intend to use the semi-automated process peri-
odically to scan the literature for new data to insert, with
follow-up (formal) systematic reviews every few years to
ensure high data quality.
In addition, a study was initially rejected during the sys-
tematic review due to lack of data pertaining to the num-
ber of patients and controls carrying certain alleles (i.e.
statistical evidence for the association). We contacted the
authors requesting the required data; the requested
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information was supplied and therefore this study was
included post hoc (Figure 1).
Web database
To enable users to query and retrieve the information, a
web database was created. This involved inserting
the extracted data into a relational database schema
with interactive webpages built on top. The
webpages were developed with Active Server Pages
scripting environment that serves out HyperText Markup
Language (HTML) and Cascading Style Sheets (CSS). This
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Figure 1. PRISMA 2009 Flow demonstrating the procedures followed for including data sets in HLA-ADR.
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Results
Data
Seventy-four articles (plus one added post hoc) from the
initial 7978 studies from this systematic review, and an
additional 16 studies from semi-automated search, were
eligible for inclusion (Figure 1) (36). From these 91 articles,
all are case–control studies with 1350 ADR-allele compari-
sons (of which 221 were statistically significant associ-
ations) recorded into the database. The overall data cover
25 distinct drugs—carbamazepine being the most fre-
quently reported (29 studies) and six drug groups were not
separated when reported in the original study. The associ-
ations covered 16 different types of ADR phenotypes,
which were tested against a total of 386 distinct HLA al-
leles (328 high-resolution allelesþ 58 serotype/antigens) in
the patient and control cohorts from these studies. The al-
leles represent 12 genes from the HLA family. A list of all
the studies present in the database can be found on the
website using the URL: http://www.allelefrequencies.net/
hla-adr/adr_data_source.asp.
The demographic data from these studies showed that
the investigations were predominantly performed on the
Asian and European continents, representing 60% and
23% of the included studies, respectively. Because many of
the investigations controlled for ethnicity by using patient
cohorts comprised of just one ethnic group, it is not sur-
prising that Asian and European cohorts made up the ma-
jority of the ethnic groups that are represented in the
database.
Website organization
Webpages created for accessing and submitting data to
HLA-ADR were integrated into the AFND website and
can be accessed either through the AFND main web-portal
or directly with the URL: http://www.allelefrequencies.net/
hla-adr. From this link, users have the option to view the
HLA-ADR query page or the HLA-ADR reports page, and
to submit studies to the database.
Query page
The query page allows users to retrieve data via the use of
dropdown filters (Figure 2) where users may select associ-
ations with certain conditions. The dropdowns are divided
into three sets; with the first set, users may choose the
HLA gene, a specific allele or a non-standard allele (e.g. a
serotype/antigen). The options within this set are mutually
exclusive, meaning the user may only apply a filter from
one of these although the user may use an option from this
set in combination with filters from the other sets. The se-
cond set of options allow the user to specify additional par-
ameters, specifically: a drug, patient ethnicity, strength of
the association (P values), the country/region where the
study was conducted or the condition for which the pa-
tients are being treated for (e.g. epilepsy). The filters from
this set can be applied in combination with each other. The
final set allows the users to choose which order they wish
the data to be presented (e.g. group all the results from in-
dividual studies together, keep associated alleles together
or by drug name). The use of dropdown options for this
database allows for fine-tuning of the search allowing users
to view associations matching their desired criteria.
Once the database is queried, the results are displayed
in a table format with each row displaying information for
each specific association. For simplicity of display, sum-
mary information about each record is provided: a link to
the PubMed/Medline abstract for the original study, the
drug, tested allele, the patient/control cohort ethnicity, the
strength of the association and the number of patients and
controls in the study cohort carrying the allele. A link is
also provided (‘More Details’) whereby the complete data
are shown for that specific association. A second link
(‘Allele Distribution’) connects to the main AFND site
showing the worldwide distribution of the allele on a map
of the world (Figure 3).
Reports page
In addition to query page, an HLA ADR report page is
also provided (Figure 4). Here, the webpage allows the
user to select a particular drug and returns all database
Figure 2. Screenshot of the HLA-ADR query page. Users can query the database via the use of filters. They may choose to see associations for genes/
alleles, drugs, patient ethnicity, level of significance (P values) and the country/region where the study was conducted.
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records pertaining to that drug, which are statistically sig-
nificant (the user may select the significance threshold). An
optional filter also enables filtering by the patient group.
The returned entries are initially provided as a summary
table—indicating alleles that have been reported, statistical
significance values and whether the association implies
that the allele is a risk or protective marker.
In addition, the report provides relevant information
embedded from other resources. First, for each allele, the
worldwide distribution is displayed on a map. Second,
search results (from AFND) for HLA haplotype frequen-
cies (in which each allele can reside) are displayed. This
feature is potentially useful for identifying if two different
alleles reported to be associated with a given ADR are in
Figure 3. A, Screenshot of the results page where ‘abacavir’ was used as the search criteria. The results show the PubMed/MEDLINE link, the drug fea-
tured in the study, the tested allele for the associations, the patient/control cohort ethnicity, the statistical evidence, links to ‘More Details’ and AFND
worldwide distributions for that allele. B, A screenshot generated by AFND showing worldwide distributions for the queried allele (e.g. HLA-B*57:01
for abacavir hypersensitivity). This page will be displayed by clicking on the allele distribution link seen in A.
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linkage disequilibrium, and thus unlikely to be independ-
ent (different) causative risk factors. Multiple sequence
alignments (MSA) powered by IMGT/HLA (13) are then
provided for all of the reported alleles (grouped by genes).
The MSA is performed using the alleles of the same gene
from the summary table along with 10 common alleles for
this gene to provide as comparison or controls. The pur-
pose of this feature is to enable users to examine whether
different alleles reported to be associated with a given
ADR may share sequence similarities that are absent from
other common (control) alleles. Finally, the report page
embeds the IMGT/HLA allele report. This provides the
user with information about the allele, such as publications
reporting the allele along with the protein, nucleotide and
genomic sequences for the allele.
Authors’ submission page
A webpage has been provided whereby authors may sub-
mit their own data. The page provides links to download a
tutorial file and a spreadsheet document to complete. Once
the data have been entered and saved onto the spreadsheet
document, the user can upload the completed file using the
authors’ submission page. We encourage researchers with
data to include their own data, both published and
non-published as well as data that show non-significant as-
sociations. We believe that this will improve the ability to
perform meta-analyses using the database. This will also
ensure that HLA-ADR stays up-to-date in this fast moving
field.
Discussion
It is evident that information relating to ADRs will con-
tinue to grow, and thus it is important that data sets and
results are digitized to enable clinicians and researchers to
access them from a centralized location. In response, we
have performed a systematic review and developed a web-
based database to provide flexible access. To ensure that
the system can be maintained and kept up-to-date, we have
added a data submission page enabling users to submit
their own studies. In addition, as HLA-ADR is part of the
wider AFND site (which has been running successfully
for>10 years), the AFND team will now include ADR
data in their regular cycles of curation.
We envisage that the database will predominantly be
used in pharmacogenetics research, e.g. enabling scientists
to perform meta-analyses in a straightforward manner
using HLA-ADR as a single resource. Moreover, the links
to external resources, such as to IMGT/HLA and the main
AFND utilities will provide users with a starting point
from which to conduct further informatics investigation.
Users should be aware we display information as they ap-
pear in the original source study without further interpret-
ation as to the reliability of a statistical association. We
have only made changes, with notifications, when we con-
sidered it absolutely necessary (e.g. if the allele association
in the study was reported with the old nomenclature sys-
tem and can be unambiguously updated to the modern no-
menclature). The risk/protective allele designation on the
reports page is the only instance where we have placed an
interpretation on the data. This was done to address the
Figure 4. Screenshot of the AFND ADR reports page from a search for drug¼aspirin, with the other options remaining at their default settings
(P< 0.05 and no restrictions on patient ethnicity). A link is provided to the DrugBank page for the drug underneath the search bar. Much like the HLA-
ADR query page, the summary table of results show the PubMed/MEDLINE link, the associated allele, the statistical data and a link to the ‘More de-
tails’ page where full details about the association can be found. In addition, a ‘risk/protective’ allele assignment is given (red or green box) based on
the proportion of carriers of the allele in the patients group compared with the control group.
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issue where certain associations are statistically significant,
but are clinically immaterial (apparent protective alleles).
Often, for the investigation of ADRs, these need to be
treated differently to risk alleles, and as such, we felt it ap-
propriate to highlight these. In a clinical setting, HLA-
ADR provides clinicians access to information about
worldwide/ethnicity-based distributions of alleles, and inci-
dence of ADRs for a given drug that can aid in clinical de-
cision making by enabling the potential risk to be assessed
more effectively.
Although data from a relatively large number of studies
have been entered to date, to ensure quality of data, we
have applied very strict inclusion criteria. However, if we
see sufficient demand from users, the database may be ex-
panded to include studies previously not included, e.g.
those that report alleles resolved to the antigen level (low
resolution or to the first field). In addition, one current
limitation to the database is that it does not include unpub-
lished data—which could lead to publication bias. As a re-
sult, the database does not comprehensively cover all of
the (potentially) available data. In order to address this, an
author’s submission page for HLA-ADR database has been
developed, and we encourage users to submit unpublished
data sets, including those containing no significant associ-
ations, which are otherwise inaccessible to the wider re-
search community. We will perform regular curation of
literature ourselves to extract any studies not submitted
directly from authors. We also welcome researchers and/or
authors to directly contact us to include studies already
published and those published after the release of HLA-
ADR that we have missed during our data curation. Users
can refer to out HLA-ADR database bibliography page to
view the list of studies present in the database.
Conclusion
With the amount of data in the pharmacogenetics field ever
increasing, we believe that HLA-ADR database has the po-
tential to assist ADR research and facilitate meta-analyses
as well as aiding clinicians. We will continue to develop
and expand upon the current query tools, based on user
feedback, over the coming years. We have already provided
a report page that we envisage will provide researchers with
a starting point from which to conduct further research and
eventually, aid in the understanding of the underlying
mechanisms of ADRs. We are also in the process of de-
veloping additional tools for applications in clinical settings
that will be released as this database is updated.
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